Competition to heat up in domestic anti-hepatitis B drug market
Published: 2012-12-26 07:00:00
Updated: 2012-12-26 07:00:00
Heated competition in the domestic anti-hepatitis B drug market, which has been dominated by BMS Korea’s Baraclude, is expected from next year because Yuhan Corp. and Boryung Pharm have been deploying aggressive marketing strategies for Gilead Sciences’ Viread from December.
Baraclude, a drug ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
